PanOph

Hyphema

Ocular Trauma

Key Points

  • •Traumatic hyphema is graded I–IV by AC filling; Grade IV (8-ball) has the worst prognosis — only ~35% achieve VA ≥20/40
  • •Secondary hemorrhage (rebleed) occurs in 5–30% at days 2–5; aminocaproic acid reduced rebleed from 23% to 0% in the original trial (Kutner et al., 1987)
  • •Sickle cell screen is MANDATORY in all at-risk patients — even HbAS trait changes management (no acetazolamide, lower surgical IOP threshold 24 mmHg)
  • •AVOID aspirin, NSAIDs, miotics, and prostaglandin analogues — use acetaminophen for pain, timolol for IOP
  • •Gonioscopy after hyphema resolution is essential — angle recession ≥180° requires lifelong IOP monitoring
1. Definition

Hyphema is the accumulation of blood in the anterior chamber of the eye. Traumatic hyphema, the most common type, results from tearing of iris or ciliary body blood vessels following blunt or penetrating ocular injury. The blood may be microscopic (microhyphema — suspended RBCs visible only on slit-lamp), layered, or fill the entire anterior chamber (total/8-ball hyphema).

2. Epidemiology

Traumatic hyphema has an estimated incidence of 12–20 per 100,000 population per year. Male-to-female ratio is approximately 3:1. Peak incidence in children and young adults (5–25 years). Most common cause in adults is blunt trauma (fist, ball, projectile); in children — toys, sports, and child abuse must be considered. Sports-related hyphema accounts for ~30% of cases. Spontaneous (non-traumatic) hyphema is uncommon and suggests underlying pathology (rubeosis iridis, iris melanoma, blood dyscrasias, juvenile xanthogranuloma in children).

3. Aetiology and causes

Traumatic (>90%):

  • Blunt trauma (most common): Fists, balls, projectiles, airbags — tears iris root vessels, ciliary body vessels, or major arterial circle of iris
  • Penetrating trauma: Sharp objects causing iris/ciliary body laceration
  • Iatrogenic: Post-intraocular surgery (cataract surgery, trabeculectomy, iris procedures), laser iridotomy, YAG capsulotomy

Spontaneous (non-traumatic):

  • Iris neovascularization (rubeosis iridis) — diabetes, CRVO, OIS
  • Iris/ciliary body tumors (melanoma, metastasis)
  • Iris vascular anomalies — juvenile xanthogranuloma (JXG) in children
  • Blood dyscrasias — leukemia, hemophilia, von Willebrand disease, anticoagulant use
  • IOL chafing (UGH syndrome — Uveitis-Glaucoma-Hyphema)
  • Fuchs heterochromic iridocyclitis (Amsler sign — bleeding during paracentesis)
4. Pathogenesis

Blunt trauma causes AP compression and equatorial expansion of the globe (hydraulic mechanism). This generates shearing forces on the iris and ciliary body vasculature:

  1. Tears in the iris root vessels, branches of the major arterial circle of the iris, or ciliary body vessels → hemorrhage into the anterior chamber.
  2. Blood settles inferiorly with gravity when the patient is upright (layered hyphema) or remains suspended as microhyphema.
  3. Secondary hemorrhage (rebleed): Occurs in 5–30% of cases, typically at days 2–5. Mechanism: clot lysis and retraction expose torn vessel ends → rebleeding, often more severe than initial bleed. Risk factors: aspirin/NSAID use, larger initial hyphema, sickle cell disease, young age, poor compliance.
  4. IOP elevation mechanisms: (a) Trabecular meshwork obstruction by RBCs, fibrin, debris; (b) Pupillary block by organized clot; (c) TM inflammation/swelling; (d) In sickle cell — sickled RBCs are rigid and obstruct TM more effectively, even small amounts cause significant IOP rise.
  5. Corneal blood staining: Occurs with persistent total hyphema + elevated IOP — hemoglobin and hemosiderin deposits in corneal stroma. More common with endothelial dysfunction.
5. Classification

Grading by extent of AC filling (Sheppard):

  • Microhyphema: RBCs suspended in aqueous, visible only on slit-lamp; no layered blood
  • Grade I: Blood occupying <1/3 of anterior chamber
  • Grade II: Blood filling 1/3–1/2 of anterior chamber
  • Grade III: Blood filling 1/2 to near-total anterior chamber
  • Grade IV (Total/8-ball hyphema): Complete filling; if bright red = fresh; if dark/black (8-ball) = deoxygenated, clotted → higher risk of complications

Alternate classification by height of blood level (in mm) — more precise for monitoring progression or resolution.

6. Risk factors and associations

Risk factors for hyphema:

  • Blunt trauma (most important)
  • Male sex, young age
  • Contact sports, occupational hazard
  • Anticoagulant/antiplatelet therapy

Risk factors for rebleed (secondary hemorrhage):

  • Aspirin/NSAID use (avoid for 2 weeks)
  • Larger initial hyphema (Grade III–IV)
  • Sickle cell disease/trait (HbSS, HbSC, even HbAS trait increases risk)
  • Young age (children rebleed more frequently)
  • Poor compliance with bed rest
  • Early resumption of physical activity

Risk factors for IOP elevation:

  • Larger hyphema grade
  • Sickle cell disease (rigid RBCs obstruct TM)
  • Associated angle recession
  • Total/8-ball hyphema
7. Clinical features

Symptoms: pain, blurred vision, photophobia, tearing, history of trauma (may be trivial in children).

Signs:

  • Blood in anterior chamber — layered inferiorly (if upright) or diffuse (if supine/microhyphema)
  • Decreased visual acuity (proportional to amount of blood)
  • Elevated IOP (may be normal or low initially; elevated in 25–33% of cases)
  • Corneal blood staining: yellow-brown discoloration of corneal stroma (with chronic total hyphema + raised IOP)
  • Associated findings from blunt trauma:
  • Sphincter tears (irregular pupil, traumatic mydriasis)
  • Iridodialysis (D-shaped pupil)
  • Vossius ring (iris pigment on lens capsule)
  • Lens subluxation (phacodonesis, iridodonesis)
  • Angle recession (on gonioscopy after hyphema clears)
  • Commotio retinae, vitreous hemorrhage, retinal dialysis
  • Cyclodialysis cleft (hypotony)

In sickle cell disease:

  • Even small (microhyphema/Grade I) can cause severe IOP elevation
  • Higher risk of optic nerve damage at lower IOP thresholds (impaired optic disc perfusion)
  • Sickling of RBCs in hypoxic anterior chamber environment
8. Investigations

Essential:

  • Visual acuity
  • IOP measurement (Goldmann or Tono-Pen; avoid air-puff if open globe suspected)
  • Slit-lamp examination: grade hyphema, document clot presence, corneal blood staining, lens position, fibrin
  • Pupil assessment: RAPD → indicates posterior segment damage
  • Sickle cell screen: Hemoglobin electrophoresis or Sickledex in all at-risk patients (African, Mediterranean, Middle Eastern descent) — CRITICAL as it changes management

After hyphema clears:

  • Gonioscopy: assess for angle recession (widened ciliary body band); perform on both eyes for comparison
  • Dilated fundoscopy: commotio retinae, choroidal rupture, retinal dialysis, vitreous hemorrhage

Imaging:

  • B-scan ultrasound: if fundal view obscured — assess for retinal detachment, VH, lens dislocation, IOFB
  • CT orbit: if suspected open globe, IOFB, or orbital fracture
  • UBM: cyclodialysis cleft evaluation

Lab:

  • PT/INR, aPTT if on anticoagulants or spontaneous hyphema
  • CBC, bleeding time if blood dyscrasia suspected
  • Consider child abuse workup if history inconsistent
9. Differential diagnosis
  • Spontaneous hyphema (non-traumatic): No trauma history; must rule out rubeosis iridis (NVG), iris melanoma, JXG, UGH syndrome, blood dyscrasias
  • Juvenile xanthogranuloma (JXG): Spontaneous hyphema in infants/young children; yellow-orange iris nodule; skin lesions may be present
  • Iris melanoma/metastasis: Pigmented or amelanotic mass on iris; chronic/recurrent hyphema; sector heterochromia
  • UGH syndrome: Uveitis-Glaucoma-Hyphema triad in pseudophakic eye; IOL chafing against iris/ciliary body
  • Herpes zoster ophthalmicus with anterior uveitis: May cause hyphema; dermatologic vesicles in V1 distribution
  • Leukemia/blood dyscrasias: Spontaneous bleeding; systemic symptoms; abnormal CBC
10. Complications

Acute:

  • Secondary hemorrhage (rebleed): Days 2–5 in 5–30%; often worse than initial bleed; higher risk of corneal blood staining and IOP elevation
  • Elevated IOP (25–33% of cases)
  • Corneal blood staining: Requires persistent total hyphema + raised IOP (usually >25 mmHg for >5 days); yellow-brown discoloration; may take 1–3 years to clear
  • Peripheral anterior synechiae (PAS)
  • Posterior synechiae
  • Pupillary block glaucoma (from organized clot)
  • Optic nerve damage from IOP elevation (at lower IOP thresholds in sickle cell)

Chronic/late:

  • Angle recession glaucoma: From associated angle damage; may develop months to decades later
  • Amblyopia: In children — from prolonged visual deprivation
  • Ghost cell glaucoma: Degenerated RBCs (khaki-colored ghost cells) from vitreous hemorrhage obstruct TM; onset weeks after injury
  • Hemolytic/hemosiderotic glaucoma: hemolysis products clog trabecular meshwork
11. Management

Conservative (mainstay for Grades I–II):

  • Bed rest with head elevated 30–45° (allows blood to settle inferiorly away from visual axis and promotes trabecular drainage)
  • Rigid eye shield (no pressure patch)
  • Topical corticosteroid: prednisolone acetate 1% q4–6h (reduces inflammation, may reduce rebleed risk)
  • Topical cycloplegic: atropine 1% BD (pain relief, stabilizes blood-aqueous barrier, reduces synechiae)
  • Analgesics: acetaminophen/paracetamol ONLY; STRICTLY AVOID aspirin, NSAIDs (inhibit platelet function, increase rebleed risk)
  • Antiemetics: ondansetron PRN (prevent Valsalva)
  • Avoid strenuous activity for ≥2 weeks

IOP management:

  • Timolol 0.5% BD (first-line)
  • Brimonidine 0.15% BD (avoid in children <2 years — CNS depression)
  • Oral/IV acetazolamide 250–500 mg q6–8h if topical insufficient
  • AVOID acetazolamide in sickle cell patients (promotes sickling in AC by acidification and concentrating HbS); use IV mannitol 1–2 g/kg instead
  • AVOID prostaglandin analogues (pro-inflammatory, promote bleeding)
  • AVOID miotics (pilocarpine increases inflammation, promotes synechiae)

Aminocaproic acid (ACA) for rebleed prevention:

  • Oral ACA 50 mg/kg q4h (max 30 g/day) for 5 days — original Kutner trial (100 mg/kg) reduced rebleed from 23% to 0%; subsequent studies showed 50 mg/kg equally effective with fewer side effects
  • Alternative: tranexamic acid 25 mg/kg TDS orally for 5 days
  • Side effects: nausea, hypotension, clot retention

Surgical — Anterior chamber washout indications:

  • Total (Grade IV) hyphema not resolving by day 4–5 (to prevent corneal blood staining)
  • IOP >50 mmHg for >5 days or >35 mmHg for >7 days despite maximal medical therapy
  • In sickle cell: IOP >24 mmHg for >24 hours (lower threshold due to increased optic nerve susceptibility)
  • Corneal blood staining (early washout limits staining duration)
  • Visually significant organized clot

Surgical technique: Paracentesis or limbal incision → irrigate/aspirate clot from AC → may use tPA (25 mcg intracameral) if organized clot; automated anterior vitrectomy if clot adherent

Follow-up:

  • Daily IOP and hyphema grading for first week
  • After resolution: gonioscopy to assess angle recession
  • Annual IOP monitoring lifelong if angle recession ≥180°
  • Children: amblyopia screening
12. Prognosis

Overall, ~85% of patients with traumatic hyphema achieve final VA ≥20/40.

  • Grade I: Excellent — >90% achieve ≥20/40; most resolve within 5–6 days
  • Grade II: Good — ~80% achieve ≥20/40
  • Grade III: Guarded — higher risk of complications
  • Grade IV (total/8-ball): Poor — only ~35% achieve VA ≥20/40; 50–75% have poor visual outcomes; high risk of corneal blood staining, secondary glaucoma, surgical intervention required

Rebleed worsens prognosis significantly.

Sickle cell disease/trait: Worse prognosis at every grade — optic nerve damage at lower IOP thresholds; earlier and more aggressive surgical intervention warranted.

Corneal blood staining: Takes 1–3 years to clear (clears from periphery inward); children at risk for deprivation amblyopia.

Long-term: Angle recession glaucoma risk persists lifelong — estimated 7–9% of patients with ≥180° angle recession develop glaucoma.

Clinical Pearls

1
Always order a sickle cell screen in at-risk patients with hyphema — even sickle trait (HbAS) is sufficient to cause severe complications, and management changes significantly (no acetazolamide, lower IOP threshold for surgery).
2
The rebleed risk peaks at days 2–5 as the initial clot retracts and lyses; aminocaproic acid (100 mg/kg q4h) reduced rebleed from 23% to 0% in Kutner et al., 1987; tranexamic acid is an alternative antifibrinolytic.
3
AVOID aspirin and NSAIDs for analgesia in hyphema — use acetaminophen only; aspirin inhibits platelet function and significantly increases rebleed risk.
4
Corneal blood staining occurs with the triad of total hyphema + elevated IOP + endothelial dysfunction; in children, it mandates urgent surgical washout to prevent deprivation amblyopia.
5
After hyphema resolution, gonioscopy is essential — angle recession ≥180° requires lifelong annual IOP monitoring for late-onset glaucoma.
6
Exam trap — Grading: Grade I: Blood filling =<1/3 of AC. Grade II: 1/3–1/2. Grade III: >1/2 but not total. Grade IV: Total hyphema (8-ball hyphema)== — entire AC filled; only ~35% achieve ≥20/40; highest risk of IOP spike, corneal blood staining, and optic atrophy.
7
Exam trap — Sickle cell and hyphema: In sickle cell trait or disease, even small hyphemas are dangerous. Sickled RBCs obstruct the trabecular meshwork at lower IOP thresholds and are less responsive to standard treatment. Avoid CAIs (acetazolamide causes metabolic acidosis → promotes sickling in aqueous). Avoid hyperosmotic agents (dehydration promotes sickling). Check sickle cell screen in ALL Black patients with hyphema.
8
Exam trap — Rebleed risk: The risk of secondary hemorrhage (rebleed) is 10–20% and peaks on days 3–5 after initial injury (when the clot retracts and lyses). Rebleeds are often larger than the initial hyphema and carry worse prognosis. Bed rest, shield, avoid aspirin/NSAIDs, and aminocaproic acid (Amicar) 50mg/kg QID (antifibrinolytic) reduces rebleed risk to 5%.
9
Exam trap — Corneal blood staining: Occurs with persistent total hyphema + elevated IOP (usually IOP >25 mmHg for >5 days). Hemoglobin-derived products deposit in the corneal stroma, causing yellow-brown discoloration. It may take months to years to clear and can cause permanent amblyopia in children. Surgical washout indicated if IOP remains elevated despite maximum medical therapy.

Oral-exam questions

  • Why must you screen for sickle cell in hyphema? — Even sickle trait (HbAS) causes sickled RBCs in the hypoxic anterior chamber → rigid cells obstruct TM → IOP rises at lower levels. Management changes: no acetazolamide (acidifies AC, promotes sickling), lower surgical threshold (>24 mmHg for >24 hours).
  • What is the mechanism of aminocaproic acid? — Inhibits conversion of plasminogen to plasmin, thereby stabilizing the fibrin clot at torn iris/ciliary body vessels and preventing premature clot dissolution. Original trial (100 mg/kg) reduced rebleed from 23% to 0% (Kutner et al., 1987); 50 mg/kg is equally effective with fewer side effects.
  • What are the indications for surgical AC washout? — (1) IOP >50 mmHg × 5 days or >35 mmHg × 7 days; (2) In sickle cell: >24 mmHg × 24 hours; (3) Total hyphema not clearing by day 4–5; (4) Corneal blood staining.
  • What is corneal blood staining? — Hemoglobin and hemosiderin deposit in the corneal stroma from persistent total hyphema with elevated IOP (usually >25 mmHg for >5 days). Appears as yellow-brown discoloration. Takes 1–3 years to clear (periphery to centre). In children → deprivation amblyopia.
  • What is ghost cell glaucoma? — Degenerated RBCs (khaki-coloured, spherical, rigid) from old vitreous hemorrhage migrate to AC and clog TM. Onset weeks to months after injury. Diagnosis: khaki cells on AC tap. Treatment: AC washout ± vitrectomy.
  • How does UGH syndrome cause hyphema? — IOL malposition or haptic chafing against iris/ciliary body causes chronic, recurrent microtrauma → Uveitis + Glaucoma + Hyphema triad. Treatment: IOL exchange or repositioning.
  • When is surgical washout indicated for hyphema? — Surgical evacuation (AC washout) is indicated for: (1) Total hyphema (Grade IV) with IOP >50 mmHg for >5 days (risk of optic atrophy) or IOP >25 mmHg for >5 days with corneal blood staining. (2) Grade IV hyphema in sickle cell patients with IOP >24 mmHg for >24 hours. (3) Non-resolving hyphema by 5–7 days with persistently elevated IOP despite maximum medical therapy.

Mnemonics

HYPHEMA

H — Head elevated 30–45° Y — Yield (avoid) aspirin/NSAIDs P — Prednisolone + atropine topical H — Hb electrophoresis (sickle screen) E — Elevate concern if IOP rises M — Manage IOP (timolol; no CAIs in sickle cell) A — Aminocaproic acid to prevent rebleed

8-BALL (Grade IV complications)

8 — 8-ball = total hyphema (dark/black blood) B — Blood staining of cornea A — Amblyopia risk in children L — Late glaucoma (angle recession) L — Low visual prognosis (<20/200 in 50–60%)

Comparison Tables

Hyphema Grading and Prognosis
Microhyphema
AC Filling
Suspended RBCs only
Rebleed Risk
Low
Visual Prognosis (≥20/40)
>95%
Special Considerations
May be missed without slit lamp
Grade I
AC Filling
<1/3 AC
Rebleed Risk
~5–10%
Visual Prognosis (≥20/40)
>90%
Special Considerations
Usually resolves 5–6 days
Grade II
AC Filling
1/3–1/2 AC
Rebleed Risk
~10–20%
Visual Prognosis (≥20/40)
~80%
Special Considerations
Monitor closely for progression
Grade III
AC Filling
1/2 to near-total
Rebleed Risk
~20–30%
Visual Prognosis (≥20/40)
Variable
Special Considerations
High complication risk
Grade IV (8-ball)
AC Filling
Total filling
Rebleed Risk
~30%+
Visual Prognosis (≥20/40)
Only ~35% achieve ≥20/40
Special Considerations
Surgical washout likely needed; dark blood = worst
Standard vs Sickle Cell Hyphema Management
IOP lowering: first-line
Standard Management
Timolol 0.5% BD
Sickle Cell (HbSS/SC/AS)
Timolol 0.5% BD (same)
IOP lowering: oral
Standard Management
Acetazolamide 250–500 mg
Sickle Cell (HbSS/SC/AS)
CONTRAINDICATED — use IV mannitol instead
Surgical threshold
Standard Management
>50 mmHg × 5 days or >35 mmHg × 7 days
Sickle Cell (HbSS/SC/AS)
>24 mmHg × 24 hours (much lower threshold)
Rationale
Standard Management
Standard optic nerve tolerance
Sickle Cell (HbSS/SC/AS)
Impaired optic disc perfusion; sickled RBCs obstruct TM at lower levels
Additional risk
Standard Management
Standard rebleed risk
Sickle Cell (HbSS/SC/AS)
Higher sickling in hypoxic AC; worse at every grade
Monitoring
Standard Management
Daily × 1 week
Sickle Cell (HbSS/SC/AS)
More frequent; lower threshold for intervention
Drugs to AVOID in Hyphema
Aspirin/NSAIDs
Reason to Avoid
Inhibit platelet function → increase rebleed risk
Alternative
Acetaminophen/paracetamol only
Prostaglandin analogues (latanoprost)
Reason to Avoid
Pro-inflammatory, may promote bleeding
Alternative
Timolol, brimonidine
Miotics (pilocarpine)
Reason to Avoid
Increase inflammation, promote synechiae
Alternative
Atropine 1% (cycloplegic)
Acetazolamide (in sickle cell)
Reason to Avoid
Acidifies AC, promotes HbS sickling
Alternative
IV mannitol 1–2 g/kg

Self-Assessment (5)

MCQ

A 12-year-old boy presents with traumatic hyphema after being hit by a cricket ball. He is of African descent. Which investigation is MOST critical before starting medical management?

MCQ

According to the aminocaproic acid trial (Kutner et al., 1987), oral aminocaproic acid reduced secondary hemorrhage in traumatic hyphema from:

MCQ

A patient with Grade IV (8-ball) hyphema and sickle cell trait has IOP of 28 mmHg for 36 hours. What is the next step?

MCQ

Which of the following is NOT an appropriate medication for traumatic hyphema?

MCQ

A child with traumatic hyphema develops yellow-brown discoloration of the corneal stroma at 2 weeks. What is the diagnosis, and what is the main concern in a child?

References

  1. Kutner B, Fourman S, Brein K, et al. Aminocaproic acid reduces the risk of secondary hemorrhage in patients with traumatic hyphema. Arch Ophthalmol. 1987;105(2):206-208.
  2. Walton W, Von Hagen S, Grigorian R, Zarbin M. Management of traumatic hyphema. Surv Ophthalmol. 2002;47(4):297-334.
  3. AAO Focal Points: Traumatic Hyphema — Current Strategies (2013).
  4. Kuhn F, Pieramici DJ. Ocular Trauma: Principles and Practice, 1st Edition. Thieme, 2002.
  5. Gervasio KA, Peck TJ, et al. The Wills Eye Manual: Office and Emergency Room Diagnosis and Treatment of Eye Disease, 8th Edition. Wolters Kluwer, 2022.
  6. Salmon JF. Kanski's Clinical Ophthalmology: A Systematic Approach, 9th Edition. Elsevier, 2020.
  7. Brandt MT, Haug RH. Traumatic hyphema: a comprehensive review. J Oral Maxillofac Surg. 2001;59(12):1462-1470.

Related Content

Aminocaproic Acid for Traumatic HyphemaBETT — Birmingham Eye Trauma TerminologyBlunt TraumaOpen Globe InjuryNeovascular GlaucomaTraumatic CataractTraumatic Hyphema
Was this helpful?

Topic complete

Continue to another topic when you are ready.

Previous topic← Eyelid lacerationNext topicIntraocular foreign body